Skip to main content
Top
Published in: BMC Nephrology 1/2016

Open Access 01-12-2016 | Research article

Clinical outcomes associated with albuminuria in central Australia: a cohort study

Authors: Rebecca Ritte, Joanne Luke, Craig Nelson, Alex Brown, Kerin O’Dea, Alicia Jenkins, James D. Best, Robyn McDermott, Mark Daniel, Kevin Rowley

Published in: BMC Nephrology | Issue 1/2016

Login to get access

Abstract

Background

Chronic kidney disease (CKD) and end-stage-kidney disease (ESKD) continue to be under-diagnosed and a major burden for Aboriginal communities in central Australia. The aim of this study was to examine the risk of poor clinical outcomes associated with elevated albumin-to-creatinine ratio (ACR) among Aboriginal people in central Australia.

Methods

Cox proportional hazards models were used to estimate the risk of end stage kidney disease (ESKD), dialysis, CVD (cardiovascular disease) and mortality associated with participants’ baseline albuminuria reading from a 10-year cohort study of Aboriginal people (n = 623) from three communities in central Australia. Predictors of progression of albuminuria were also examined in the context of the Kidney Health Australia (KHA) Risk Matrix.

Results

A baseline ACR level of ≥3.5 mg/mmol was associated with an almost 10-fold increased risk of ESKD (95%CI 2.07-43.8) and a 15-fold risk of dialysis (95%CI 1.89-121). Albuminuria ≥3.5 mg/mmol was also associated with a borderline 63 % increased risk of CVD (95%CI 0.98-2.71). No significant association was observed with mortality from all-causes or chronic disease. Diabetes and a waist-to-hip ratio ≥0.90 independently predicted a two-fold increased risk of a progression to higher ACR levels.

Conclusions

A single measure of moderately increased albuminuria was a strong predictor of renal failure in this population. A single spot urine ACR analysis in conjunction with the KHA Risk Matrix may be a useful and efficient strategy to screen for risk of CKD and progression to dialysis in remote communities. A focus on individuals with diabetes and/or central obesity for strategies to avoid increases in albuminuria may also prevent future CKD and CVD complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stumpers S, Thomson N. Review of kidney disease among Indigenous people. Australian Indigenous HealthInfoNet: Online; 2013. Stumpers S, Thomson N. Review of kidney disease among Indigenous people. Australian Indigenous HealthInfoNet: Online; 2013.
2.
go back to reference Hoy WE, Kincaid-Smith P, Hughson MD, Fogo AB, Sinniah R, Dowling J, Samuel T, Mott SA, Douglas-Denton RN, Bertram JF. CKD in Aboriginal Australians. Am J Kidney Dis. 2010;56(5):983–93.CrossRefPubMed Hoy WE, Kincaid-Smith P, Hughson MD, Fogo AB, Sinniah R, Dowling J, Samuel T, Mott SA, Douglas-Denton RN, Bertram JF. CKD in Aboriginal Australians. Am J Kidney Dis. 2010;56(5):983–93.CrossRefPubMed
3.
go back to reference Hoy W, McDonald SP. Albuminuria: marker or target in indigenous populations. Kidney Int Suppl. 2004;92:S25–31.CrossRef Hoy W, McDonald SP. Albuminuria: marker or target in indigenous populations. Kidney Int Suppl. 2004;92:S25–31.CrossRef
4.
go back to reference White A, Wong W, Sureshkumur P, Singh G. The burden of kidney disease in indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease. J Paediatr Child Health. 2010;46(9):504–9.CrossRefPubMed White A, Wong W, Sureshkumur P, Singh G. The burden of kidney disease in indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease. J Paediatr Child Health. 2010;46(9):504–9.CrossRefPubMed
5.
go back to reference Hoy WE, Mathews JD, McCredie DA, Pugsley DJ, Hayhurst BG, Rees M, Kile E, Walker KA, Wang Z. The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int. 1998;54(4):1296–304.CrossRefPubMed Hoy WE, Mathews JD, McCredie DA, Pugsley DJ, Hayhurst BG, Rees M, Kile E, Walker KA, Wang Z. The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int. 1998;54(4):1296–304.CrossRefPubMed
6.
go back to reference Preston-Thomas A, Cass A, O’Rourke P. Trends in the incidence of treated end-stage kidney disease among Indigenous Australians and access to treatment. Aust N Z J Public Health. 2007;31(5):419–21.CrossRefPubMed Preston-Thomas A, Cass A, O’Rourke P. Trends in the incidence of treated end-stage kidney disease among Indigenous Australians and access to treatment. Aust N Z J Public Health. 2007;31(5):419–21.CrossRefPubMed
7.
go back to reference Australian Institute of Health and Welfare (AIHW): Heart, Stroke and Vascular Diseases Australian Facts 2004. In. Canberra; 2004. Australian Institute of Health and Welfare (AIHW): Heart, Stroke and Vascular Diseases Australian Facts 2004. In. Canberra; 2004.
8.
go back to reference Australian Institute of Health and Welfare (AIHW): Chronic Kidney Disease in Aboriginal and Torres Strait Islander People 2011. In. Canberra: AIHW; 2011 Australian Institute of Health and Welfare (AIHW): Chronic Kidney Disease in Aboriginal and Torres Strait Islander People 2011. In. Canberra: AIHW; 2011
9.
go back to reference Shephard MD, Allen GG, Barratt LJ, Barbara JA, Paizis K, McLeod G, Brown M, Vanajek A. Albuminuria in a remote South Australian Aboriginal community: results of a community-based screening program for renal disease. Rural Remote Health. 2003;3(1):156.PubMed Shephard MD, Allen GG, Barratt LJ, Barbara JA, Paizis K, McLeod G, Brown M, Vanajek A. Albuminuria in a remote South Australian Aboriginal community: results of a community-based screening program for renal disease. Rural Remote Health. 2003;3(1):156.PubMed
10.
go back to reference Mathew T, Corso O. Review article: Early detection of chronic kidney disease in Australia: which way to go? Nephrology (Carlton). 2009;14(4):367–73.CrossRef Mathew T, Corso O. Review article: Early detection of chronic kidney disease in Australia: which way to go? Nephrology (Carlton). 2009;14(4):367–73.CrossRef
11.
go back to reference Kidney Health Australia: Chronic Kidney Disease (CKD) Management in General Practice (2nd edition). In. Melbourne; 2012. Kidney Health Australia: Chronic Kidney Disease (CKD) Management in General Practice (2nd edition). In. Melbourne; 2012.
12.
go back to reference Zhao Y, Connors C, Wright J, Guthridge S, Bailie R. Estimating chronic disease prevalence among the remote Aboriginal population of the Northern Territory using multiple data sources. Aust N Z J Public Health. 2008;32(4):307–13.CrossRefPubMed Zhao Y, Connors C, Wright J, Guthridge S, Bailie R. Estimating chronic disease prevalence among the remote Aboriginal population of the Northern Territory using multiple data sources. Aust N Z J Public Health. 2008;32(4):307–13.CrossRefPubMed
13.
go back to reference Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.CrossRefPubMedPubMedCentral Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.CrossRefPubMedPubMedCentral
14.
go back to reference Johnson DW, Jones GRD, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, Polkinghorne K, Colagiuri S, Jerums G, MacIsaac R, et al. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust. 2012;197(4):224–5. Johnson DW, Jones GRD, Mathew TH, Ludlow MJ, Chadban SJ, Usherwood T, Polkinghorne K, Colagiuri S, Jerums G, MacIsaac R, et al. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust. 2012;197(4):224–5.
15.
go back to reference Central Australian Rural Practictioners Association (CARPA): CARPA Standard Treatment Manual, 6th Edition edn. Alice Springs; 2014. Central Australian Rural Practictioners Association (CARPA): CARPA Standard Treatment Manual, 6th Edition edn. Alice Springs; 2014.
16.
go back to reference Shephard MD, Allen GG, Paizis K, Barbara JA, Batterham M, Vanajek A. Results of an Aboriginal community-based renal disease management program incorporating point of care testing for urine albumin:creatinine ratio. Rural Remote Health. 2006;6(4):591.PubMed Shephard MD, Allen GG, Paizis K, Barbara JA, Batterham M, Vanajek A. Results of an Aboriginal community-based renal disease management program incorporating point of care testing for urine albumin:creatinine ratio. Rural Remote Health. 2006;6(4):591.PubMed
17.
go back to reference Luke JN, Brown AD, Brazionis L, O’Dea K, Best JD, McDermott RA, Wang Z, Rowley KG. Exploring clinical predictors of cardiovascular disease in a central Australian Aboriginal cohort. Eur J Prev Cardiol. 2013;20(2):246–53.CrossRefPubMed Luke JN, Brown AD, Brazionis L, O’Dea K, Best JD, McDermott RA, Wang Z, Rowley KG. Exploring clinical predictors of cardiovascular disease in a central Australian Aboriginal cohort. Eur J Prev Cardiol. 2013;20(2):246–53.CrossRefPubMed
18.
go back to reference Rowley KG, Iser DM, Best JD, O’Dea K, Leonard D, McDermott R. Albuminuria in Australian Aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia. 2000;43(11):1397–403.CrossRefPubMed Rowley KG, Iser DM, Best JD, O’Dea K, Leonard D, McDermott R. Albuminuria in Australian Aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia. 2000;43(11):1397–403.CrossRefPubMed
19.
go back to reference Luke JN, Brown A, O’Neal DN, O’Dea K, Jenkins AJ, Kelaher M, Best JD, Rowley KG. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Med J Aust. 2009;190(10):552–6.PubMed Luke JN, Brown A, O’Neal DN, O’Dea K, Jenkins AJ, Kelaher M, Best JD, Rowley KG. Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Med J Aust. 2009;190(10):552–6.PubMed
20.
go back to reference Kidney Disease Improving Global Outcomes (KDIGO): KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements 2013;3(1):1-150. Kidney Disease Improving Global Outcomes (KDIGO): KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements 2013;3(1):1-150.
21.
go back to reference Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J. 2009;157(6, Supplement):S7–S16.CrossRefPubMed Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J. 2009;157(6, Supplement):S7–S16.CrossRefPubMed
22.
go back to reference Hoy WE, Wang Z, VanBuynder P, Baker PR, McDonald SM, Mathews JD. The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure. Kidney Int. 2001;60(1):249–56.CrossRefPubMed Hoy WE, Wang Z, VanBuynder P, Baker PR, McDonald SM, Mathews JD. The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure. Kidney Int. 2001;60(1):249–56.CrossRefPubMed
23.
go back to reference Rowley K, O’Dea K, Best JD. Association of albuminuria and the metabolic syndrome. Curr Diab Rep. 2003;3(1):80–6.CrossRefPubMed Rowley K, O’Dea K, Best JD. Association of albuminuria and the metabolic syndrome. Curr Diab Rep. 2003;3(1):80–6.CrossRefPubMed
24.
go back to reference Ninomiya T, Kiyohara Y. Albuminuria and chronic kidney disease in association with the metabolic syndrome. J Cardiometab Syndr. 2007;2(2):104–7.CrossRefPubMed Ninomiya T, Kiyohara Y. Albuminuria and chronic kidney disease in association with the metabolic syndrome. J Cardiometab Syndr. 2007;2(2):104–7.CrossRefPubMed
25.
go back to reference Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant. 2003;18(10):2170–4.CrossRefPubMed Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant. 2003;18(10):2170–4.CrossRefPubMed
26.
go back to reference Wu HY, Huang Jw Fau - Peng Y-S, Peng Ys Fau - Hung K-Y, Hung Ky Fau - Wu K-D, Wu Kd Fau - Lai M-S, Lai Ms Fau - Chien K-L, Chien KL: Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review. Renal Failure 2012(1525–6049 (Electronic)). Wu HY, Huang Jw Fau - Peng Y-S, Peng Ys Fau - Hung K-Y, Hung Ky Fau - Wu K-D, Wu Kd Fau - Lai M-S, Lai Ms Fau - Chien K-L, Chien KL: Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review. Renal Failure 2012(1525–6049 (Electronic)).
28.
go back to reference Registry A. Indigenous People & End Stage Kidney Disease. In: Preliminary Report 2014: Summary of Dialysis and Transplantation in Australia and New Zealand. 37th ed. Adelaide: ANZDATA Registry; 2015. p. 1–24. Registry A. Indigenous People & End Stage Kidney Disease. In: Preliminary Report 2014: Summary of Dialysis and Transplantation in Australia and New Zealand. 37th ed. Adelaide: ANZDATA Registry; 2015. p. 1–24.
29.
go back to reference Baker PR, Hoy WE, Thomas RE. Cost-effectiveness analysis of a kidney and cardiovascular disease treatment program in an Australian Aboriginal population. Adv Chronic Kidney Dis. 2005;12(1):22–31.CrossRefPubMed Baker PR, Hoy WE, Thomas RE. Cost-effectiveness analysis of a kidney and cardiovascular disease treatment program in an Australian Aboriginal population. Adv Chronic Kidney Dis. 2005;12(1):22–31.CrossRefPubMed
30.
go back to reference Hoy WE, Wang Z, Baker PR, Kelly AM. Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int Suppl. 2003;83:S66–73.CrossRef Hoy WE, Wang Z, Baker PR, Kelly AM. Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int Suppl. 2003;83:S66–73.CrossRef
31.
go back to reference Cass A, Cunningham J, Wang Z, Hoy W. Social disadvantage and variation in the incidence of end-stage renal disease in Australian capital cities. Aust N Z J Public Health. 2001;25(4):322–6.CrossRefPubMed Cass A, Cunningham J, Wang Z, Hoy W. Social disadvantage and variation in the incidence of end-stage renal disease in Australian capital cities. Aust N Z J Public Health. 2001;25(4):322–6.CrossRefPubMed
32.
go back to reference Naresh CN, Hayen A Fau - Craig JC, Craig Jc Fau - Chadban SJ, Chadban SJ: Day-to-day variability in spot urine protein-creatinine ratio measurements. American Journal of Kidney Disease 2012(1523–6838 (Electronic)). Naresh CN, Hayen A Fau - Craig JC, Craig Jc Fau - Chadban SJ, Chadban SJ: Day-to-day variability in spot urine protein-creatinine ratio measurements. American Journal of Kidney Disease 2012(1523–6838 (Electronic)).
33.
go back to reference Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, Zimmet PZ, Chadban SJ, Polkinghorne KR, Shaw JE, et al. High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID study. BMC Public Health. 2011;11:346.CrossRefPubMedPubMedCentral Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, Zimmet PZ, Chadban SJ, Polkinghorne KR, Shaw JE, et al. High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID study. BMC Public Health. 2011;11:346.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical outcomes associated with albuminuria in central Australia: a cohort study
Authors
Rebecca Ritte
Joanne Luke
Craig Nelson
Alex Brown
Kerin O’Dea
Alicia Jenkins
James D. Best
Robyn McDermott
Mark Daniel
Kevin Rowley
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-016-0328-1

Other articles of this Issue 1/2016

BMC Nephrology 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine